Navigation Links
Sepsis and Septic Shock on the Rise, Affecting Younger Patients
Date:1/11/2010

DURHAM, N.C., Jan. 11 /PRNewswire/ -- bioMerieux, a world leader in the field of in vitro diagnostics, today released its results of a comprehensive survey of emergency department and critical care physicians. The vast majority of these doctors reported that sepsis and septic shock--the result of serious infections--is on the rise in U.S. hospitals, affecting increasingly younger patients. The surveyed doctors attributed the increase to the overuse of antibiotics, which is rendering these once wonder-drugs ineffective.

Sepsis, a usually fatal medical condition caused by the body's response to a severe infection of the blood and/or tissues, affects 5-10 percent of all hospital patients, leading to an increase of about $5 billion in U.S. health-care costs annually.(1) Nearly 300 emergency and critical care doctors were surveyed at two major medical conferences - the American College of Emergency Physicians Annual Conference, held in Boston in October 2009, and the American College of Chest Physicians Annual Meeting, held in San Diego in November 2009.

When asked if they have seen an increasing rate in sepsis in their hospitals during the last decade, the answer was unequivocally "yes." Seventy-six percent of the physicians surveyed said the incidence of sepsis is on the rise. In addition, nearly 60 percent said sepsis is affecting more patients than it did 10 years ago.

Sixty-three percent of doctors surveyed indicated that the No. 1 reason for younger patients becoming septic was an increase in multi-drug-resistant microorganisms, which is caused by the widespread overuse of antibiotics. In a recent study published by Roberts et al, examining the hospital and societal costs of antibiotic-resistant infections (ARIs) at a Chicago hospital, patients who suffered from these infections remained in the hospital between 6.4-12.7 days longer than those who were not infected and had a significantly increased risk of death - two-fold higher than in patients without ARIs, with an attributable mortality rate of 6.5 percent.(2)

"Sepsis is often a life-threatening condition, compounded by multidrug-resistant organisms and patients who live longer with serious underlying co-morbidities," said Mark H. Oltermann, M.D., director of the Medical ICU at John Peter Smith Hospital in Fort Worth, Texas.

When asked if biomarkers, or telltale biochemical indicators of infection, are used to help diagnose severe infections that could lead to sepsis, the vast majority (nearly 70 percent) of the 281 surveyed doctors said yes. However, only 6 percent of these doctors reported using procalcitonin (PCT) as a biomarker to help them manage suspected sepsis patients. When asked to qualify the improvement that PCT testing could bring to emergency and critical care patients, 51 percent said the test would dramatically improve the quality of care that patients with suspected sepsis would receive in U.S. hospitals.

"Sepsis is a disease that when diagnosed early and treated effectively, more lives can be saved than almost any other disease," Dr. Oltermann added. "It is critical that we add state-of-the art tools to our arsenal to help battle sepsis. PCT is one of those tools."

To review the complete results of the 2009 Sepsis Survey Report, which covers additional aspects of sepsis diagnosis and care, infectious diseases biomarkers, and how ED and CC physicians rank in importance the timely issues of health-care reform, liability reform, and the emergence of multidrug-resistant organisms, please visit www.biomerieux-usa.com/knowfromday1.

About Procalcitonin (PCT)

PCT is the prohormone of calcitonin and is not normally present in the bloodstream of a healthy individual. PCT is released from multiple organs when there is a systemic bacterial infection. The blood plasma level of PCT is a reflection of the severity of bacterial infection, ranging from slightly elevated concentrations in infections with minor systemic inflammatory response to very high values in cases of severe sepsis and septic shock. Since the first report in 1993 on the association of serum PCT levels with bacterial infection,(3) there is a solid body of evidence in the literature on its utility for early diagnosis and prognosis, monitoring the clinical course as well as its utility to guide therapy.(4)

References

  1. Balk, R. Severe Sepsis and Septic Shock: Definitions, Epidemiology, And Clinical Manifestations; Critical Care Clinics, Volume 16, Issue 2, Pages 179-192.
  2. Roberts RR, Hota B, Ahmad I, Scott RD II, Foster SD, Abbasi F, Schabowski S, Kampe LM, Ciavarella GG, Supino M, Naples J, Cordell R, Levy SB, Weistein RA. Hospital and Societal Costs of Antimicrobial-Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic Stewardship. Clin Infect Dis 2009:49 (15 October):1175-84.
  3. Assicot M, Gendrel D, Garsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341: 515-518.
  4. Christ-Crain M, Muller B. Procalcitonin in bacterial infections - hype, hope or more or less? Swiss Med Wkly 2005; 135: 451-460.

About bioMerieux

Advancing diagnostics to improve public health

A world leader in the field of in vitro diagnostics for more than 45 years, bioMerieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2008, revenues reached 1.111 billion euros with 84% of sales outside of France. bioMerieux provides diagnostic solutions (reagents, instruments, software) that determine the source of disease and contamination to improve patient health and ensure consumer safety. Our products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMerieux is listed on the NYSE Euronext Paris market (Symbol: BIM - ISIN: FR0010096479). Other information can be found at www.biomerieux.com.

SOURCE bioMerieux

RELATED LINKS
http://www.biomerieux.com

'/>"/>

SOURCE bioMerieux
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
2. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
3. Results From Phase II Trial in Critical Care Medicine Showed Eritoran Tetrasodium (E5564) To Be Well Tolerated in Patients with Severe Sepsis
4. Medizone International, Inc. (MZEI.PK): Trials of the AsepticSure Hospital Sterilization System Have Begun
5. Hand Washing with 4% CHG Antiseptic Kills Flu Viruses
6. Medizone International Announces Third Round of AsepticSure
7. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
8. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
9. With 2009 H1N1 Cases on the Rise, New CDC-Recommended Vaccine Helps Protect Families Against Illness
10. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
11. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- Walgreens has committed to provide drug disposal kiosks ... D.C. as part of a program to combat ... advocacy organization As You Sow. Conrad MacKerron , ... on to unneeded drugs because they lack easily accessible collection ... --> Conrad MacKerron , Senior Vice President at As ...
(Date:2/11/2016)... 11, 2016   Health 2.0 , the premiere ... technologies, announced today " 10 Year Global Retrospective ", ... over the past ten years.   ... Health 2.0 has served as the preeminent thought-leader in ... thousands of technologies, companies, innovators, and patient-activists through an ...
(Date:2/11/2016)... , Feb. 11, 2016  NOIT™ Research LLC, a ... "Gift of Change" campaign to assist needy families in ... such unit sold between February 10, 2016 and March ... a needy family. The NOIT is an auditory stimulus ... individuals develop language skills. Beth Shier ...
Breaking Medicine Technology:
(Date:2/11/2016)... Alpharetta, Georgia (PRWEB) , ... February 11, 2016 ... ... Physicians Group (DMPG) will use the action analytics leader’s population health solutions, ... analytics and clinical support to the Atlanta-area healthcare system. Details of the contract ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... wide range of cosmetic procedures. Along with performing procedures, the magazine also highlights ... of many cosmetic procedures. One of the most common procedures he performs is ...
(Date:2/11/2016)... ... February 11, 2016 , ... Image One USA veteran ... market, and it’s the buildings of Nashville that will benefit. , “I’ve enjoyed being ... relocate to Nashville, there was no question that I would bring my business with ...
(Date:2/11/2016)... ... February 11, 2016 , ... Hall Integrative Health ... up for their simultaneous grand openings in March. All seven practices are set ... probably wondering, is reversing diabetes possible? According to this 2011 CNN article it ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... Plastic and Reconstructive Surgery, Dallas plastic surgeon , Dr. Rod J. Rohrich, ... rhinoplasty surgery . Dr. Rohrich outlines recommendations for rhinoplasty surgeons when addressing this ...
Breaking Medicine News(10 mins):